Yeah I think Hygro thought they were making the an argument that the trial was flawed but you are right on the mark if the FDA believed this allegation that a larger number of treatments improves effectiveness it is all the more reason to approve. When it is all said and done isn't that what is important, common sense vs splitting hairs on p values or some other criteria especially for those with orphan designation.